MedTrace Logo

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

NCT00971425 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2018-08-17

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.

Conditions

Interventions

BIOLOGICAL

Pandemrix (GSK investigational influenza GSK2340272A vaccine)

2 doses intramuscular injections

BIOLOGICAL

Fluarix™

1 dose intramuscular injection

BIOLOGICAL

Placebo

1 dose intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
61 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-08
Primary Completion
2009-11-16
Completion
2010-10-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00971425 on ClinicalTrials.gov